Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI Player

Catalysts

About CapsoVision

CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics.

What are the underlying business or industry changes driving this perspective?

• Growing physician and clinic adoption of minimally invasive GI screening, supported by 151,000 cumulative CapsoCam Plus patients and recent approvals for pediatric use and remote ingestion, can expand procedure volumes and support higher revenue over time.
• Increasing comfort with cloud based clinical workflows, together with CPT code 91110 reimbursement, positions the fully cloud hosted CapsoCloud platform to gain share in GI practices and hospitals while helping protect gross margin through reduced on site hardware cost.
• Advancement of AI capabilities, including the planned 510(k) submission for AI integration into CapsoCam Plus and the large, identified image database on CapsoCloud, can improve reading efficiency and diagnostic accuracy, which may support higher utilization and more attractive earnings over time.
• Broader interest in early cancer detection and noninvasive screening, reflected in CapsoVision's Breakthrough Device Designation application for pancreatic ductal adenocarcinoma and progress in CapsoCam Colon pivotal work, could open additional high value indications that expand the revenue base beyond small bowel procedures.
• Industry wide demand for higher quality imaging in endoscopy, together with CapsoVision's agreement with Canon to co develop next generation CMOS sensors, may support differentiated future products that justify premium pricing and help improve net margins as R&D spending on this program normalizes from the Q3 2025 level.

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming CapsoVision's revenue will grow by 74.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from -172.4% today to 5.8% in 3 years time.
• Analysts expect earnings to reach $4.0 million (and earnings per share of $0.07) by about January 2029, up from $-22.6 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 185.8x on those 2029 earnings, up from -12.5x today. This future PE is greater than the current PE for the US Medical Equipment industry at 32.0x.
• Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.67%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• CapsoVision is still loss making, with a net loss of $7.9 million in the third quarter of 2025 on revenue of $3.5 million, and rising operating expenses linked to R&D, public company costs and stock based compensation could keep net margins and earnings under pressure for longer than investors expect.
• The Canon CMOS sensor program and other pipeline projects are adding meaningful R&D costs today, while management has indicated the sensors are not intended for current products and may only be ready for capsule integration after 2026. This introduces the risk of extended cash burn without near term revenue contribution, weighing on earnings and potentially requiring further capital raises that increase the share count.
• Regulatory timelines are already slipping, with the AI 510(k) submission for CapsoCam Plus pushed out due to third party resource constraints and key programs like CapsoCam Colon Gen 2 and pancreatic applications dependent on future FDA decisions. Any further delays or unsuccessful submissions could slow procedure growth and limit future revenue relative to expectations.
• The long term thesis relies heavily on AI and cloud based workflows. Rival GI or imaging companies may also build strong AI capabilities or alternative noninvasive tools, which could cap pricing power for capsules and compress gross margin if CapsoVision needs to compete more aggressively on price.
• Adoption in hospitals, GPOs and international markets is still at an earlier stage. If reimbursement frameworks, large account renewals or distributor relationships do not scale as management intends, procedure volumes might fall short of the high growth narrative, limiting revenue growth and delaying any turn toward positive net margins and earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $10.5 for CapsoVision based on their expectations of its future earnings growth, profit margins and other risk factors.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $7.0.
  
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $69.3 million, earnings will come to $4.0 million, and it would be trading on a PE ratio of 185.8x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $6.0, the analyst price target of $10.5 is 42.9% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.